Posted by Michael Wonder on 01 Jun 2021
Akebia and Otsuka announce FDA acceptance for filing of new drug application for vadadustat for the treatment of anaemia due to chronic kidney disease in adult patients on dialysis and not on dialysis
1 June 2021 - Vadadustat assigned PDUFA target action date of 29 March 2022.
Akebia Therapeutics and its collaborator Otsuka today announced that the U.S. FDA accepted for filing the new drug application for vadadustat for the treatment of anaemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.
